Clinical Trials

Neuroendocrine Tumors

NCT05477576 2026-03-30

ACTION-1

Phase 3 Recruiting

338 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT07377487 2026-03-30

INDIGO

Phase NA Recruiting

51 enrolled

Carcinoma, Colonic Diseases, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Colorectal Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT06943755 2026-03-24

STELLAR-311

Phase 2/3 Recruiting

440 enrolled

Adenoma, Islet Cell, Neoplasm Metastasis, Neuroendocrine Tumors

NCT04727723 2026-03-20

REAL-LU

Active not recruiting

164 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT05361668 2026-03-19

Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

Phase 2 Completed

36 enrolled 19 charts

Carcinoid Tumors, Intestinal, Carcinoid Tumor, Neuroendocrine Tumors, Serotonin Syndrome

NCT07087054 2026-03-10

CAREFNDR

Phase 3 Recruiting

141 enrolled

Carcinoid Tumors, Intestinal, Carcinoid Tumor, Neuroendocrine Tumors, Serotonin Syndrome

NCT07129252 2026-03-10

BRAVESST2

150 enrolled

Phase 2 Active not recruiting

Neoplasm Metastasis, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT02568267 2026-03-06

STARTRK-2

534 enrolled 2 FDA

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidNETSarcomaThoracic

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT04471727 2026-02-24

MK-6070-001

Phase 1/2 Active not recruiting

232 enrolled

EndocrineGenitourinaryNETThoracic

Lung Neoplasms, Prostatic Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT06055439 2026-01-29

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

135 enrolled

Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors

NCT07369505 2026-01-27

Sapu003 in Advanced mTOR-sensitive Solid Tumors

EndocrineGastrointestinalGenitourinaryNET

27 enrolled

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Tuberous Sclerosis, Neuroendocrine Tumors

NCT04373564 2026-01-22

ODYSSEY

Phase 4 Recruiting

2,076 enrolled

BreastEndocrineGastrointestinalGenitourinaryNET

Breast Neoplasms, Carcinoma, Hepatocellular, Prostatic Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors

NCT03600233 2025-12-23

Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors

Phase 2 Active not recruiting

34 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Adenoma, Islet Cell, Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT03691064 2025-12-23

SALUS

Active not recruiting

1,014 enrolled

Neuroendocrine Tumors

NCT06441331 2025-12-17

KinLET

CNSEndocrineGastrointestinalLymphoidNETSarcoma

20 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Lymphoma, Rhabdomyosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Neuroendocrine Tumors

NCT06943521 2025-12-11

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

BreastEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETSarcomaThoracic

27 enrolled

Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Endometrial Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT05636618 2025-11-24

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors

CNSEndocrineGastrointestinalNET

260 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT02270567 2025-11-13

RegisterNET

Enrolling by invitation

400 enrolled

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidMyeloidNETOther hematologic neoplasmThoracic

Carcinoid Tumor, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Disease Progression

NCT03452774 2025-10-28

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Recruiting

50,000 enrolled

Turcot syndrome, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioblastoma, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Laryngeal Neoplasms, Leukemia, Liver Neoplasms, Lung Neoplasms, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Skin Neoplasms, Stomach Neoplasms, Testicular Neoplasms, Central Nervous System Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Primary Myelofibrosis

NCT03910660 2025-10-20

A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

EndocrineGenitourinaryNET

98 enrolled

Prostatic Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

NCT06805825 2025-09-23

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

DermatologicEndocrineGastrointestinalGenitourinaryNETSarcomaThoracic

67 enrolled

Uveal Melanoma, Carcinoma, Renal Cell, Carcinoma, Adenoid Cystic, Piebaldism, Neuroendocrine Tumors, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma

NCT02628067 2025-09-22

KEYNOTE 158

Phase 2 Active not recruiting

1,609 enrolled 9 FDA

EndocrineGastrointestinalGynecologicHead & NeckNETOther solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Anus Neoplasms, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoid Tumor, Uterine Cervical Neoplasms, Mesothelioma, Parotid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Microsatellite Instability, Small Cell Lung Carcinoma

NCT06358001 2025-09-22

EchoTip AcuCore Post-Market Clinical Study

Completed

183 enrolled

EndocrineGastrointestinalLymphoidNET

Autoimmune Pancreatitis, Adenocarcinoma, Carcinoma, Hepatocellular, Lymphoma, Neoplasm Metastasis, Cholangiocarcinoma, Neuroendocrine Tumors, Pancreatitis, Chronic

NCT06505824 2025-09-18

A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors

22 enrolled

EndocrineNETThoracic

Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT05077384 2025-09-16

Open-label Study of Surufatinib in Japanese Patients

36 enrolled

Neuroendocrine Tumors

NCT06577987 2025-09-15

Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies

BreastEndocrineNETThoracic

220 enrolled

Breast Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Triple Negative Breast Neoplasms

NCT04919226 2025-09-10

COMPOSE

Phase 3 Active not recruiting

259 enrolled

Phase 3 Active not recruiting

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT05459844 2025-09-05

A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

196 enrolled

Neuroendocrine Tumors

NCT05017662 2025-09-04

A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072

Phase NA Completed

20 enrolled

Neuroendocrine Tumors

NCT04579679 2025-07-25

Open-Label Surufatinib in European Patients With NET

Phase 2 Terminated

78 enrolled 20 charts

Neuroendocrine Tumors

NCT02611024 2025-07-09

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

CNSEndocrineGastrointestinalGynecologicNETOther solid neoplasmSarcomaThoracic

316 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

NCT02279433 2025-06-24

A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b

Phase 1 Completed

46 enrolled

EndocrineGastrointestinalNETThoracic

Lung Neoplasms, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors

NCT03466216 2025-06-10

Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET

Phase 1 Terminated

33 enrolled

Neuroendocrine Tumors

NCT03037385 2025-05-31

ARROW

590 enrolled 58 charts 8 FDA

EndocrineGastrointestinalHead & NeckNETThoracic

Thyroid Cancer, Papillary, Adenocarcinoma, Adenocarcinoma, Papillary, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Diseases, Colonic Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Glandular and Epithelial, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Colorectal Neoplasms, Neuroectodermal Tumors, Carcinoma, Medullary, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 2a

NCT04579757 2025-05-08

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Phase 1/2 Terminated

87 enrolled 29 charts

EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

NCT05167071 2025-04-27

HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study

Phase 1 Active not recruiting

53 enrolled

Neuroendocrine Tumors

NCT04893759 2025-04-17

A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors

Phase 1 Terminated

2 enrolled

EndocrineGynecologicNETThoracic

Neuroendocrine Tumors

NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Phase 2 Completed

139 enrolled 14 charts

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

NCT02464007 2025-02-25

Study of rSIFN-co for Patients With Advanced Solid Tumors

Phase 1 Terminated

7 enrolled

Neuroendocrine Tumors

NCT04438304 2025-02-12

A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)

Phase 2 Completed

45 enrolled

Neuroendocrine Tumors

NCT04524442 2025-01-24

Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

Phase 4 Completed

42 enrolled 11 charts

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Neuroendocrine Tumors

NCT05879055 2024-12-19

A Study of PM8002 in Combination With Chemotherapy in Patients With NEN

Phase 2 Recruiting

60 enrolled

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidMyeloidNETOther hematologic neoplasmOther solid neoplasmPlasma cellSarcomaThoracic

Neuroendocrine Tumors

NCT04028479 2024-12-18

ROOT

Completed

167 enrolled

Nasopharyngeal Carcinoma, Adenocarcinoma, Adrenal Gland Neoplasms, Anus Neoplasms, Appendiceal Neoplasms, Astrocytoma, Bile Duct Neoplasms, Urinary Bladder Neoplasms, Bone Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoid Tumor, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Chondrosarcoma, Colonic Neoplasms, Carcinoma, Adenoid Cystic, Esophageal Neoplasms, Fallopian Tube Neoplasms, Glioblastoma, Head and Neck Neoplasms, Kidney Neoplasms, Laryngeal Neoplasms, Liposarcoma, Liver Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Melanoma, Mesothelioma, Multiple Myeloma, Neoplasms, Multiple Endocrine Neoplasia, Neoplasms, Unknown Primary, Ovarian Neoplasms, Pancreatic Neoplasms, Parathyroid Neoplasms, Parotid Neoplasms, Penile Neoplasms, Pharyngeal Neoplasms, Pheochromocytoma, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Sarcoma, Sarcoma, Kaposi, Osteosarcoma, Skin Neoplasms, Stomach Neoplasms, Sarcoma, Synovial, Testicular Neoplasms, Thymus Neoplasms, Thyroid Neoplasms, Tongue Neoplasms, Ureteral Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Central Nervous System Neoplasms, Cholangiocarcinoma, Carcinoma, Small Cell, Neuroendocrine Tumors, Brain Stem Neoplasms, Gestational Trophoblastic Disease, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04649580 2024-12-17

PREF-NET

Completed

80 enrolled